Owing to the heterogeneity of cancer, oncology markets are increasingly focusing on personalized therapy approaches that are expected to provide greater efficacy gains. Driving this trend are…
Gastric cancer (GC) is a major public health burden in China and is the third leading cause of cancer-related deaths in the country. Although chemotherapy is the mainstay of treatment, prescribing…
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. It is the seventh most common type of cancer worldwide and the second most common cause of cancer death worldwide. Most risk…
Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Are emerging targeted therapies poised to fill the significant unmet need of patients in the second and subsequent lines of therapy? Treatment decisions for non-small-cell lung cancer (NSCLC)…
LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib)…
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…
Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…
Treatment Choices Are Limited, but Oncologists’ Receptivity to Targeted Agents Presents a Lucrative Opportunity The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/Chugai…
What attributes will distinguish emerging therapies in the eyes of oncologists and payers? Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for…
What attributes will distinguish emerging therapies in the eyes of oncologists and payers? Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for…
Treatment for breast cancer (CaB) in the United States has matured as oncologists have formalized protocols around specific patient populations, namely HER2+, HR+/HER2-, and HR-/HER2- (also known…
LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab)…
Oncology prescribing has changed with the broad adoption of clinical pathways programs, bundled payment arrangements, and accountable care organizations (ACOs). Each of these managed care reforms…
LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…